This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
I’d like to start with our forward-looking statements, as I will be making comments that are forward-looking in nature pertaining to our other development and commercialization of our product candidates. I’d refer everyone to our quarterly and annual filings of the SEC, available on the Avanir website, or on the SEC’s website.
Avanir is a uniquely positioned specialty biopharmaceutical company focused on CNS therapies. Our lead product compound NUEDEXTA was approved in late 2010 as the first and only therapy for the treatment of pseudobulbar affect. Subsequent to the FDA approval in late 2010, we launched NUEDEXTA in February of last year approximately one year ago, and since launch we’ve seen a steady and continued growth in both physician adoption and prescription, and I’ll get into more detail later in the presentation about pseudobulbar affect, as well as our commercial launch of NUEDEXTA.
In addition, with arguably the largest hurdle behind us, that being FDA approval, it opens up NUEDEXTA, or as we call it in clinical development, AVP-923, for a number of additional indications. Those listed on the slide include: central neuropathic pain in multiple sclerosis, behavioral disturbances in Alzheimer’s patients and a host of a number other potential indications. And many of you may have seen this morning, an announcement that we made in regards to a license agreement with Concert Pharmaceuticals, and that license agreement gave us access to their deuterated dextromethorphan, and we really view that as a next-generation dextromethorphan with the potential in all of these indications that I mentioned, and I’ll go into more detail on these indications – potential indications as well as the Concert deal later in the presentation.